Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11114681 | 0.93 | TACR1 (0.49) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL3595674 | 0.89 | TACR1 (0.54) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL1923485 | 0.85 | TSHR (0.45) | TACR1TSHRSLC1A1HTR2AHRH1 | |
| SCHEMBL7967707 | 0.83 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL7965700 | 0.83 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL2781643 | 0.83 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL3587032 | 0.83 | TACR1 (0.43) | TACR1CA1CA2CA9 | |
| SCHEMBL5025103 | 0.83 | IDO1 (0.43) | TACR1 | |
| SCHEMBL18394417 | 0.83 | TACR1 (0.63) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL24215414 | 0.82 | TACR1 (0.54) | TACR1TSHRSLC1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | claimed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | claimed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | claimed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | TACR1 19/4885TSHR 41/4885SLC1A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.